Ofloxacin

Ofloxacin and Ornidazole is a broad-spectrum fixed-dose antimicrobial combination pairing a fluoroquinolone with a nitroimidazole. Ofloxacin halts bacterial DNA multiplication, while ornidazole damages microbial DNA through free nitro radicals, eradicating anaerobes and protozoa. Indicated for mixed bacterial and protozoal gastroenteritis, amoebic dysentery, pelvic inflammatory disease, dental infections, and post-surgical abdominal sepsis.

Ofloxacin is a synthetic fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and repair. Broad-spectrum activity encompasses Gram-negative bacteria, Chlamydia trachomatis, Mycoplasma, and Mycobacterium tuberculosis (second-line). Indicated for acute exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated urethral and cervical gonorrhoea, pelvic inflammatory disease, and complicated UTIs.

Ofloxacin is a synthetic fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and repair. Broad-spectrum activity encompasses Gram-negative bacteria, Chlamydia trachomatis, Mycoplasma, and Mycobacterium tuberculosis (second-line). Indicated for acute exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated urethral and cervical gonorrhoea, pelvic inflammatory disease, and complicated UTIs.

Cefixime and Ofloxacin is a fixed-dose combination antibiotic combining a 3rd-generation cephalosporin and a broad-spectrum fluoroquinolone. Cefixime inhibits cell wall synthesis, while ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, halting DNA replication. This dual mechanism provides synergistic bactericidal coverage against resistant pathogens. Indicated for enteric fever (typhoid fever), severe respiratory tract infections, complicated urinary tract infections, and mixed bacterial pelvic infections.

Ofloxacin is a synthetic fluoroquinolone bactericidal antibiotic. It acts by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and repair. Broad-spectrum activity encompasses Gram-negative bacteria, Chlamydia trachomatis, Mycoplasma, and Mycobacterium tuberculosis (second-line). Indicated for acute exacerbations of chronic bronchitis, community-acquired pneumonia, uncomplicated urethral and cervical gonorrhoea, pelvic inflammatory disease, and complicated UTIs.

Ofloxacin Eye Drops 0.3% w/v is an evidence-based ophthalmic/otic formulation. It acts by delivering targeted active therapeutic substances to external ocular or auditory tissues to control infection, relieve inflammation, or restore tissue homeostasis.

Ofloxacin 0.3% w/v + Dexamethasone 0.1% w/v + Benzalkonium Chloride (As Preservative) 0.005% w/v Eye Drops is an evidence-based ophthalmic/otic formulation. It acts by delivering targeted active therapeutic substances to external ocular or auditory tissues to control infection, relieve inflammation, or restore tissue homeostasis.

Cefpodoxime Proxetil and Ofloxacin is a broad-spectrum combination of an oral 3rd-generation cephalosporin prodrug and a second-generation fluoroquinolone. Cefpodoxime blocks cell wall synthesis while ofloxacin halts DNA replication and transcription via bacterial DNA gyrase and topoisomerase IV inhibition. Indicated for mixed and resistant respiratory tract infections, enteric fever, and complicated skin or urinary infections.

Ceruminolytic Ear Drop formulation combining Paradichlorobenzene (2%), Chlorbutol (5%), Turpentine Oil (15%), and Lidocaine (2%). Paradichlorobenzene hydrates and dissolves hard impacted cerumen; turpentine oil acts as a counter-irritant and cerumen liquefier; chlorbutol provides mild antibacterial and antifungal preservation; and lidocaine relieves localized ear canal pain and tension. Indicated for softening, loosening, and removal of hardened, impacted ear wax.

Ofloxacin and Metronidazole oral suspension is a dual antimicrobial formulation for mixed paediatric and adult gastrointestinal and systemic infections. Ofloxacin inhibits bacterial DNA gyrase, while metronidazole disrupts anaerobic and protozoal helical DNA structure. Indicated for bacterial and amoebic diarrhea, dysentery, giardiasis, and mixed aerobic-anaerobic infections.